Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management

Medicine & Life Sciences

• Leukemia, Myelomonocytic, Chronic 100%
• Risk Management 74%
• Molecular Models 52%
• Mutation 30%
• Monocytes 22%
• Developmental Bone Disease 20%
• Azacitidine 18%
• Decitabine 17%
• Frameshift Mutation 16%
• Myelodysplastic Syndromes 15%
• Survival 15%
• Allogeneic Cells 14%
• Myeloid Cells 13%
• Hematopoietic Stem Cells 13%
• Chromosome Aberrations 13%
• Platelet Count 13%
• Hemoglobins 11%
• Stem Cells 10%
• Bone Marrow 10%
• Alleles 10%
• Transplants 8%
• Morbidity 8%
• Mortality 6%
• Genes 5%
• Neoplasms 4%
• Therapeutics 2%